We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| DaVita Inc | NYSE:DVA | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -7.79 | -5.48% | 134.45 | 145.84 | 131.27 | 145.84 | 2,541,406 | 00:51:57 |
From May 2019 to May 2024
NEW YORK, Feb. 12, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of DaVita Healthcare Partners Inc. ("DaVita" or "the Company") (NYSE: DVA). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
This investigation concerns whether DaVita and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act").
On February 11, 2016, post-market, DaVita released that the U.S. Attorney's Office for the Northern District of Texas it had sent a Civil Investigative Demand (CID) about a False Claims Act investigation into allegations that it submitted false claims to the government for prescription drug reimbursement dating back to January 1, 2006.
Following this news, the DaVita stock dropped as much as $1.99, or 3.18%, to $60.58 per share on February 11, 2016 post-market.
If you are aware of any facts relating to this investigation, or purchased shares of DaVita, you can assist this investigation by visiting the firm's website: http://www.bgandg.com/#!dva/btad0. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-davita-healthcare-partners-inc-dva-300219364.html
SOURCE Bronstein, Gewirtz & Grossman, LLC
Copyright 2016 PR Newswire
1 Year DaVita Chart |
1 Month DaVita Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
